Altamira Therapeutics Ltd.
CYTOF
$0.0585
-$0.0115-16.43%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 58.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 58.70K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 994.00K | 994.00K | -- | -- | 1.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -17.10K | -17.10K | -- | -- | -38.70K |
| Total Operating Expenses | 1.96M | 1.96M | -- | -- | 1.83M |
| Operating Income | -1.96M | -1.96M | -- | -- | -1.83M |
| Income Before Tax | -2.17M | -2.17M | -- | -- | -2.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.17M | -2.17M | -- | -- | -2.26M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -710.40K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.17M | -2.17M | -- | -- | -2.97M |
| EBIT | -1.96M | -1.96M | -- | -- | -1.83M |
| EBITDA | -- | -- | -- | -- | -1.83M |
| EPS Basic | -1.05 | -1.05 | -14.16 | -14.16 | -14.16 |
| Normalized Basic EPS | -0.66 | -0.66 | -- | -- | -6.78 |
| EPS Diluted | -1.05 | -1.05 | -14.16 | -14.16 | -14.16 |
| Normalized Diluted EPS | -0.66 | -0.66 | -- | -- | -6.78 |
| Average Basic Shares Outstanding | 2.06M | 2.06M | 491.30K | -- | 210.00K |
| Average Diluted Shares Outstanding | 2.06M | 2.06M | 491.30K | 210.00K | 210.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
